131 IODINE RADIOLABELED ANTI B1 MONOCLONAL ANTIBODY IN B CELL LYMPHOMA

131 B 细胞淋巴瘤中的碘放射性标记抗 B1 单克隆抗体

• 批准号: 6274061
• 负责人: MANSOOR N SALEH
• 金额: $ 2.59万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-01-26 至 1998-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6274061
• 关键词: B cell lymphoma; B lymphocyte; clinical research; human subject; human therapy evaluation; iodine; monoclonal antibody; neoplasm /cancer immunotherapy; neoplasm /cancer radionuclide therapy; neoplastic transformation; nonHodgkin's lymphoma; radiation dosage

This is a phase II trial of the I-131 labeled radioactive anti-B1 monoclonal antibody for the treatment of low grade lymphoma, as well as transformed lymphoma. Patients who failed prior therapy generally do not have substantial options, and in general have por overall outcome. The phase I trial of the radiolabeled anti-B1 demonstrated the ability to deliver 85 cGy whole body radiation with modest reversible toxicity and was associated with significant responses in patients with refractory low grade lymphoma. The current study looks at the dose of 85 cGy whole body radiotherapy in refractory low grade lymphoma or transformed lymphoma.

这是I-131标记的放射性抗B1的II期试验 单克隆抗体治疗低度恶性淋巴瘤，以及 转化淋巴瘤 既往治疗失败的患者通常不会 有实质性的选择，一般来说，有por整体结果。 的 放射性标记抗B1的I期试验证明了 提供85 cGy的全身辐射，具有适度的可逆毒性， 与难治性低血糖患者的显著反应相关 恶性淋巴瘤 目前的研究着眼于85 cGy的全身剂量 难治性低度恶性淋巴瘤或转化淋巴瘤的放疗。